The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Diagnostic Nuclear Drug Market Research Report 2025
Synopsis
Nuclear Drugs are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis
The global Diagnostic Nuclear Drug market was valued at US$ 4722 million in 2023 and is anticipated to reach US$ 7534.8 million by 2030, witnessing a CAGR of 6.9% during the forecast period 2024-2030.
The diagnostic radioisotopes market is driven by the increasing prevalence of cancer and cardiovascular diseases, which require advanced imaging techniques for accurate diagnosis and treatment planning. Diagnostic radioisotopes are radioactive compounds used in nuclear medicine imaging to visualize and evaluate physiological processes and detect specific diseases in the body. The rise in the aging population and the need for early and precise diagnosis contribute to market growth. Moreover, advancements in radiopharmaceutical research and the development of new radioisotopes have improved the sensitivity and specificity of diagnostic imaging. However, the market also faces challenges, including the high cost of production and limited availability of some radioisotopes. Additionally, ensuring regulatory compliance and addressing concerns regarding radiation safety can pose obstacles for manufacturers and healthcare facilities. To succeed, companies must focus on research and development to offer innovative and diverse diagnostic radioisotopes, collaborate with healthcare providers to improve nuclear medicine imaging capabilities, and address the challenges to meet the increasing demand for effective and safe diagnostic imaging solutions.
This report aims to provide a comprehensive presentation of the global market for Diagnostic Nuclear Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diagnostic Nuclear Drug.
Report Scope
The Diagnostic Nuclear Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diagnostic Nuclear Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diagnostic Nuclear Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cardinal Health
GE Healthcare
Curium Pharma
Jubilant Pharma
Bracco Imaging
Novartis
SIEMENS
China Isotope & Radiation
Dongcheng
Lantheus
Eli Lilly
Segment by Type
Tc-99m
F-18
Other
Segment by Application
Oncology
Cardiology
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diagnostic Nuclear Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Nuclear Drugs are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis
The global Diagnostic Nuclear Drug market was valued at US$ 4722 million in 2023 and is anticipated to reach US$ 7534.8 million by 2030, witnessing a CAGR of 6.9% during the forecast period 2024-2030.
The diagnostic radioisotopes market is driven by the increasing prevalence of cancer and cardiovascular diseases, which require advanced imaging techniques for accurate diagnosis and treatment planning. Diagnostic radioisotopes are radioactive compounds used in nuclear medicine imaging to visualize and evaluate physiological processes and detect specific diseases in the body. The rise in the aging population and the need for early and precise diagnosis contribute to market growth. Moreover, advancements in radiopharmaceutical research and the development of new radioisotopes have improved the sensitivity and specificity of diagnostic imaging. However, the market also faces challenges, including the high cost of production and limited availability of some radioisotopes. Additionally, ensuring regulatory compliance and addressing concerns regarding radiation safety can pose obstacles for manufacturers and healthcare facilities. To succeed, companies must focus on research and development to offer innovative and diverse diagnostic radioisotopes, collaborate with healthcare providers to improve nuclear medicine imaging capabilities, and address the challenges to meet the increasing demand for effective and safe diagnostic imaging solutions.
This report aims to provide a comprehensive presentation of the global market for Diagnostic Nuclear Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diagnostic Nuclear Drug.
Report Scope
The Diagnostic Nuclear Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diagnostic Nuclear Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diagnostic Nuclear Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cardinal Health
GE Healthcare
Curium Pharma
Jubilant Pharma
Bracco Imaging
Novartis
SIEMENS
China Isotope & Radiation
Dongcheng
Lantheus
Eli Lilly
Segment by Type
Tc-99m
F-18
Other
Segment by Application
Oncology
Cardiology
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diagnostic Nuclear Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diagnostic Nuclear Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tc-99m
1.2.3 F-18
1.2.4 Other
1.3 Market by Application
1.3.1 Global Diagnostic Nuclear Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Diagnostic Nuclear Drug Market Perspective (2019-2030)
2.2 Diagnostic Nuclear Drug Growth Trends by Region
2.2.1 Global Diagnostic Nuclear Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Diagnostic Nuclear Drug Historic Market Size by Region (2019-2024)
2.2.3 Diagnostic Nuclear Drug Forecasted Market Size by Region (2025-2030)
2.3 Diagnostic Nuclear Drug Market Dynamics
2.3.1 Diagnostic Nuclear Drug Industry Trends
2.3.2 Diagnostic Nuclear Drug Market Drivers
2.3.3 Diagnostic Nuclear Drug Market Challenges
2.3.4 Diagnostic Nuclear Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diagnostic Nuclear Drug Players by Revenue
3.1.1 Global Top Diagnostic Nuclear Drug Players by Revenue (2019-2024)
3.1.2 Global Diagnostic Nuclear Drug Revenue Market Share by Players (2019-2024)
3.2 Global Diagnostic Nuclear Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Diagnostic Nuclear Drug Revenue
3.4 Global Diagnostic Nuclear Drug Market Concentration Ratio
3.4.1 Global Diagnostic Nuclear Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diagnostic Nuclear Drug Revenue in 2023
3.5 Diagnostic Nuclear Drug Key Players Head office and Area Served
3.6 Key Players Diagnostic Nuclear Drug Product Solution and Service
3.7 Date of Enter into Diagnostic Nuclear Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Diagnostic Nuclear Drug Breakdown Data by Type
4.1 Global Diagnostic Nuclear Drug Historic Market Size by Type (2019-2024)
4.2 Global Diagnostic Nuclear Drug Forecasted Market Size by Type (2025-2030)
5 Diagnostic Nuclear Drug Breakdown Data by Application
5.1 Global Diagnostic Nuclear Drug Historic Market Size by Application (2019-2024)
5.2 Global Diagnostic Nuclear Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Diagnostic Nuclear Drug Market Size (2019-2030)
6.2 North America Diagnostic Nuclear Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Diagnostic Nuclear Drug Market Size by Country (2019-2024)
6.4 North America Diagnostic Nuclear Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Diagnostic Nuclear Drug Market Size (2019-2030)
7.2 Europe Diagnostic Nuclear Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Diagnostic Nuclear Drug Market Size by Country (2019-2024)
7.4 Europe Diagnostic Nuclear Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Diagnostic Nuclear Drug Market Size (2019-2030)
8.2 Asia-Pacific Diagnostic Nuclear Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Diagnostic Nuclear Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Diagnostic Nuclear Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Diagnostic Nuclear Drug Market Size (2019-2030)
9.2 Latin America Diagnostic Nuclear Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Diagnostic Nuclear Drug Market Size by Country (2019-2024)
9.4 Latin America Diagnostic Nuclear Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diagnostic Nuclear Drug Market Size (2019-2030)
10.2 Middle East & Africa Diagnostic Nuclear Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Diagnostic Nuclear Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Diagnostic Nuclear Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cardinal Health
11.1.1 Cardinal Health Company Detail
11.1.2 Cardinal Health Business Overview
11.1.3 Cardinal Health Diagnostic Nuclear Drug Introduction
11.1.4 Cardinal Health Revenue in Diagnostic Nuclear Drug Business (2019-2024)
11.1.5 Cardinal Health Recent Development
11.2 GE Healthcare
11.2.1 GE Healthcare Company Detail
11.2.2 GE Healthcare Business Overview
11.2.3 GE Healthcare Diagnostic Nuclear Drug Introduction
11.2.4 GE Healthcare Revenue in Diagnostic Nuclear Drug Business (2019-2024)
11.2.5 GE Healthcare Recent Development
11.3 Curium Pharma
11.3.1 Curium Pharma Company Detail
11.3.2 Curium Pharma Business Overview
11.3.3 Curium Pharma Diagnostic Nuclear Drug Introduction
11.3.4 Curium Pharma Revenue in Diagnostic Nuclear Drug Business (2019-2024)
11.3.5 Curium Pharma Recent Development
11.4 Jubilant Pharma
11.4.1 Jubilant Pharma Company Detail
11.4.2 Jubilant Pharma Business Overview
11.4.3 Jubilant Pharma Diagnostic Nuclear Drug Introduction
11.4.4 Jubilant Pharma Revenue in Diagnostic Nuclear Drug Business (2019-2024)
11.4.5 Jubilant Pharma Recent Development
11.5 Bracco Imaging
11.5.1 Bracco Imaging Company Detail
11.5.2 Bracco Imaging Business Overview
11.5.3 Bracco Imaging Diagnostic Nuclear Drug Introduction
11.5.4 Bracco Imaging Revenue in Diagnostic Nuclear Drug Business (2019-2024)
11.5.5 Bracco Imaging Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Diagnostic Nuclear Drug Introduction
11.6.4 Novartis Revenue in Diagnostic Nuclear Drug Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 SIEMENS
11.7.1 SIEMENS Company Detail
11.7.2 SIEMENS Business Overview
11.7.3 SIEMENS Diagnostic Nuclear Drug Introduction
11.7.4 SIEMENS Revenue in Diagnostic Nuclear Drug Business (2019-2024)
11.7.5 SIEMENS Recent Development
11.8 China Isotope & Radiation
11.8.1 China Isotope & Radiation Company Detail
11.8.2 China Isotope & Radiation Business Overview
11.8.3 China Isotope & Radiation Diagnostic Nuclear Drug Introduction
11.8.4 China Isotope & Radiation Revenue in Diagnostic Nuclear Drug Business (2019-2024)
11.8.5 China Isotope & Radiation Recent Development
11.9 Dongcheng
11.9.1 Dongcheng Company Detail
11.9.2 Dongcheng Business Overview
11.9.3 Dongcheng Diagnostic Nuclear Drug Introduction
11.9.4 Dongcheng Revenue in Diagnostic Nuclear Drug Business (2019-2024)
11.9.5 Dongcheng Recent Development
11.10 Lantheus
11.10.1 Lantheus Company Detail
11.10.2 Lantheus Business Overview
11.10.3 Lantheus Diagnostic Nuclear Drug Introduction
11.10.4 Lantheus Revenue in Diagnostic Nuclear Drug Business (2019-2024)
11.10.5 Lantheus Recent Development
11.11 Eli Lilly
11.11.1 Eli Lilly Company Detail
11.11.2 Eli Lilly Business Overview
11.11.3 Eli Lilly Diagnostic Nuclear Drug Introduction
11.11.4 Eli Lilly Revenue in Diagnostic Nuclear Drug Business (2019-2024)
11.11.5 Eli Lilly Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Diagnostic Nuclear Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Tc-99m
Table 3. Key Players of F-18
Table 4. Key Players of Other
Table 5. Global Diagnostic Nuclear Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Diagnostic Nuclear Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Diagnostic Nuclear Drug Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Diagnostic Nuclear Drug Market Share by Region (2019-2024)
Table 9. Global Diagnostic Nuclear Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Diagnostic Nuclear Drug Market Share by Region (2025-2030)
Table 11. Diagnostic Nuclear Drug Market Trends
Table 12. Diagnostic Nuclear Drug Market Drivers
Table 13. Diagnostic Nuclear Drug Market Challenges
Table 14. Diagnostic Nuclear Drug Market Restraints
Table 15. Global Diagnostic Nuclear Drug Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Diagnostic Nuclear Drug Market Share by Players (2019-2024)
Table 17. Global Top Diagnostic Nuclear Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diagnostic Nuclear Drug as of 2023)
Table 18. Ranking of Global Top Diagnostic Nuclear Drug Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Diagnostic Nuclear Drug Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Diagnostic Nuclear Drug Product Solution and Service
Table 22. Date of Enter into Diagnostic Nuclear Drug Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Diagnostic Nuclear Drug Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Diagnostic Nuclear Drug Revenue Market Share by Type (2019-2024)
Table 26. Global Diagnostic Nuclear Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Diagnostic Nuclear Drug Revenue Market Share by Type (2025-2030)
Table 28. Global Diagnostic Nuclear Drug Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Diagnostic Nuclear Drug Revenue Market Share by Application (2019-2024)
Table 30. Global Diagnostic Nuclear Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Diagnostic Nuclear Drug Revenue Market Share by Application (2025-2030)
Table 32. North America Diagnostic Nuclear Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Diagnostic Nuclear Drug Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Diagnostic Nuclear Drug Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Diagnostic Nuclear Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Diagnostic Nuclear Drug Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Diagnostic Nuclear Drug Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Diagnostic Nuclear Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Diagnostic Nuclear Drug Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Diagnostic Nuclear Drug Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Diagnostic Nuclear Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Diagnostic Nuclear Drug Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Diagnostic Nuclear Drug Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Diagnostic Nuclear Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Diagnostic Nuclear Drug Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Diagnostic Nuclear Drug Market Size by Country (2025-2030) & (US$ Million)
Table 47. Cardinal Health Company Detail
Table 48. Cardinal Health Business Overview
Table 49. Cardinal Health Diagnostic Nuclear Drug Product
Table 50. Cardinal Health Revenue in Diagnostic Nuclear Drug Business (2019-2024) & (US$ Million)
Table 51. Cardinal Health Recent Development
Table 52. GE Healthcare Company Detail
Table 53. GE Healthcare Business Overview
Table 54. GE Healthcare Diagnostic Nuclear Drug Product
Table 55. GE Healthcare Revenue in Diagnostic Nuclear Drug Business (2019-2024) & (US$ Million)
Table 56. GE Healthcare Recent Development
Table 57. Curium Pharma Company Detail
Table 58. Curium Pharma Business Overview
Table 59. Curium Pharma Diagnostic Nuclear Drug Product
Table 60. Curium Pharma Revenue in Diagnostic Nuclear Drug Business (2019-2024) & (US$ Million)
Table 61. Curium Pharma Recent Development
Table 62. Jubilant Pharma Company Detail
Table 63. Jubilant Pharma Business Overview
Table 64. Jubilant Pharma Diagnostic Nuclear Drug Product
Table 65. Jubilant Pharma Revenue in Diagnostic Nuclear Drug Business (2019-2024) & (US$ Million)
Table 66. Jubilant Pharma Recent Development
Table 67. Bracco Imaging Company Detail
Table 68. Bracco Imaging Business Overview
Table 69. Bracco Imaging Diagnostic Nuclear Drug Product
Table 70. Bracco Imaging Revenue in Diagnostic Nuclear Drug Business (2019-2024) & (US$ Million)
Table 71. Bracco Imaging Recent Development
Table 72. Novartis Company Detail
Table 73. Novartis Business Overview
Table 74. Novartis Diagnostic Nuclear Drug Product
Table 75. Novartis Revenue in Diagnostic Nuclear Drug Business (2019-2024) & (US$ Million)
Table 76. Novartis Recent Development
Table 77. SIEMENS Company Detail
Table 78. SIEMENS Business Overview
Table 79. SIEMENS Diagnostic Nuclear Drug Product
Table 80. SIEMENS Revenue in Diagnostic Nuclear Drug Business (2019-2024) & (US$ Million)
Table 81. SIEMENS Recent Development
Table 82. China Isotope & Radiation Company Detail
Table 83. China Isotope & Radiation Business Overview
Table 84. China Isotope & Radiation Diagnostic Nuclear Drug Product
Table 85. China Isotope & Radiation Revenue in Diagnostic Nuclear Drug Business (2019-2024) & (US$ Million)
Table 86. China Isotope & Radiation Recent Development
Table 87. Dongcheng Company Detail
Table 88. Dongcheng Business Overview
Table 89. Dongcheng Diagnostic Nuclear Drug Product
Table 90. Dongcheng Revenue in Diagnostic Nuclear Drug Business (2019-2024) & (US$ Million)
Table 91. Dongcheng Recent Development
Table 92. Lantheus Company Detail
Table 93. Lantheus Business Overview
Table 94. Lantheus Diagnostic Nuclear Drug Product
Table 95. Lantheus Revenue in Diagnostic Nuclear Drug Business (2019-2024) & (US$ Million)
Table 96. Lantheus Recent Development
Table 97. Eli Lilly Company Detail
Table 98. Eli Lilly Business Overview
Table 99. Eli Lilly Diagnostic Nuclear Drug Product
Table 100. Eli Lilly Revenue in Diagnostic Nuclear Drug Business (2019-2024) & (US$ Million)
Table 101. Eli Lilly Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Diagnostic Nuclear Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Diagnostic Nuclear Drug Market Share by Type: 2023 VS 2030
Figure 3. Tc-99m Features
Figure 4. F-18 Features
Figure 5. Other Features
Figure 6. Global Diagnostic Nuclear Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Diagnostic Nuclear Drug Market Share by Application: 2023 VS 2030
Figure 8. Oncology Case Studies
Figure 9. Cardiology Case Studies
Figure 10. Other Case Studies
Figure 11. Diagnostic Nuclear Drug Report Years Considered
Figure 12. Global Diagnostic Nuclear Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Diagnostic Nuclear Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Diagnostic Nuclear Drug Market Share by Region: 2023 VS 2030
Figure 15. Global Diagnostic Nuclear Drug Market Share by Players in 2023
Figure 16. Global Top Diagnostic Nuclear Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diagnostic Nuclear Drug as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Diagnostic Nuclear Drug Revenue in 2023
Figure 18. North America Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Diagnostic Nuclear Drug Market Share by Country (2019-2030)
Figure 20. United States Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Diagnostic Nuclear Drug Market Share by Country (2019-2030)
Figure 24. Germany Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Diagnostic Nuclear Drug Market Share by Region (2019-2030)
Figure 32. China Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Diagnostic Nuclear Drug Market Share by Country (2019-2030)
Figure 40. Mexico Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Diagnostic Nuclear Drug Market Share by Country (2019-2030)
Figure 44. Turkey Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Diagnostic Nuclear Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Cardinal Health Revenue Growth Rate in Diagnostic Nuclear Drug Business (2019-2024)
Figure 47. GE Healthcare Revenue Growth Rate in Diagnostic Nuclear Drug Business (2019-2024)
Figure 48. Curium Pharma Revenue Growth Rate in Diagnostic Nuclear Drug Business (2019-2024)
Figure 49. Jubilant Pharma Revenue Growth Rate in Diagnostic Nuclear Drug Business (2019-2024)
Figure 50. Bracco Imaging Revenue Growth Rate in Diagnostic Nuclear Drug Business (2019-2024)
Figure 51. Novartis Revenue Growth Rate in Diagnostic Nuclear Drug Business (2019-2024)
Figure 52. SIEMENS Revenue Growth Rate in Diagnostic Nuclear Drug Business (2019-2024)
Figure 53. China Isotope & Radiation Revenue Growth Rate in Diagnostic Nuclear Drug Business (2019-2024)
Figure 54. Dongcheng Revenue Growth Rate in Diagnostic Nuclear Drug Business (2019-2024)
Figure 55. Lantheus Revenue Growth Rate in Diagnostic Nuclear Drug Business (2019-2024)
Figure 56. Eli Lilly Revenue Growth Rate in Diagnostic Nuclear Drug Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
